Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Hyun J Yim, Tiffany Jean, Peck Y Ong
PURPOSE OF REVIEW: Historically, systemic treatments for atopic dermatitis (AD) primarily consisted of immunosuppressive agents such as corticosteroids and Disease Modifying Antirheumatic Drugs (DMARDS), which provided symptomatic relief but often had long-term adverse effects. Newer treatments have shown significant efficacy with less side effects in clinical trials. This review discusses and compares conventional and newer systemic treatments for AD. RECENT FINDINGS: Newer medications for AD including dupilumab, tralokinumab, lebrikizumab, and oral JAK inhibitors have been shown to be safe and efficacious...
April 18, 2024: Current Allergy and Asthma Reports
#2
JOURNAL ARTICLE
Jessica Gates, Andrew Hearn, Tom Mason, Mariana Fernandes, Linda Green, Louise Thomson, Cris Roxas, Jodie Lam, Grainne d'Ancona, Alexandra M Nanzer, Jaideep Dhariwal, David J Jackson
BACKGROUND: Dupilumab is an anti-IL4R monoclonal antibody (mAb) with proven efficacy in severe eosinophilic asthma (SEA). A suboptimal response to anti-IL5/5R mAbs is seen in some patients with ongoing evidence of T2 inflammation. OBJECTIVE: To understand whether targeting IL-13 pathways with dupilumab in these patients may lead to better clinical outcomes. METHODS: We performed a retrospective analysis of the extended clinical effectiveness of dupilumab up to 2 years of treatment in patients with SEA who had not responded adequately to anti-IL5/5R biologics...
April 5, 2024: Journal of Allergy and Clinical Immunology in Practice
#3
JOURNAL ARTICLE
Manuela Latorre, Angela Rizzi, Pierluigi Paggiaro, Ilaria Baiardini, Diego Bagnasco, Stefano DelGiacco, Carlo Lombardi, Vincenzo Patella, Eleonora Nucera, Roberta Parente, Giovanni Paoletti, Laura Pini, Erminia Ridolo, Gianenrico Senna, Francesco Blasi, Giorgio Walter Canonica, Arianna Aruanno, Carmen Ballacchino, Marco Bonavia, Cecilia Calabrese, Marco Caminati, Monica Carbonara, Cristina Cardini, Cristiano Caruso, Luciano Cattani, Maria Angiola Crivellaro, Alessandra Diana, Eugenia Durante, Elisabetta Favero, Maria Pia Foschino Barbaro, Sandra Frateiacci, Gabriella Guarnieri, Alessia Lofaro, Francesca Losa, Nadia Magarò, Francesco Menzella, Luisa Ricciardi, Giulia Scioscia, Elisa Testino, Francesca Torracca
OBJECTIVE: Patients' perceptions of asthma symptoms, and attitudes regarding diagnosis and management, can affect their ability to reach good asthma control. The aim of the study was to explore patients' perceptions of asthma management, with focus on treatment with oral corticosteroids (OCS). METHODS: A DOXAPHARMA survey was conducted. A questionnaire with 46 multiple choice questions was completed by 50 patients with severe uncontrolled asthma, and 258 with mild-moderate controlled or partly controlled asthma...
April 5, 2024: Journal of Asthma
#4
Subbarayudu Boda, Venkata Narayana Badipatla, Erramelli Nag Divya, Palak Dutta, Rohit Ganduboina
INTRODUCTION AND IMPORTANCE: Churg-Strauss syndrome (CSS) is a rare multisystemic condition characterized by asthma, blood and tissue eosinophilia, and vasculitis. The purpose of this work is to present a detailed overview of CSS, focusing on its epidemiology, clinical symptoms, histological criteria, gastrointestinal involvement, and therapy. CASE PRESENTATION: The authors report a case of a 40-year-old woman with CSS who had peripheral eosinophilia, small vessel vasculitis, and bronchial asthma...
April 2024: Annals of Medicine and Surgery
#5
JOURNAL ARTICLE
Paolo Cameli, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Giorgio Walter Canonica, Cristiano Caruso, Stefano Centanni, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Gianenrico Senna, Alessandra Vultaggio, Marco Benci, Silvia Boarino, Francesco Menzella
PURPOSE: Severe eosinophilic asthma (SEA) patients often present overlapping inflammatory features rendering them eligible for multiple biologic therapies; switching biologic treatment is a strategy adopted to optimize asthma control when patients show partial or no response to previous biologics. PATIENTS AND METHODS: ANANKE is a retrospective, multicenter Italian study (NCT04272463). Here, we outline the characteristics and long-term clinical outcomes in naïve-to-biologics and biologics-experienced patients treated with benralizumab for up to 96 weeks...
2024: Journal of Asthma and Allergy
#6
JOURNAL ARTICLE
Naoki Okada, Hiroki Kabata, Yoshihito Tanaka, Tetsuya Homma, Sunao Mikura
We conducted a systematic review to examine whether step-down of inhaled corticosteroid (ICS) is recommended for adult patients with asthma have been well controlled with moderate or high-dose inhaled corticosteroids for more than 12 weeks. Seven randomized controlled trials were included. ICS step-down did not increase asthma exacerbations requiring systemic steroid therapy and hospitalization. There was no effect on respiratory function, asthma control, or QOL. No significant differences were observed in serious adverse events or steroid-related adverse events, but the observation period was insufficient to assess long-term effects...
2024: Arerugī, [Allergy]
#7
Antonio Maiorano, Chiara Lupia, Nicola Montenegro, Giuseppe Neri, Andrea Bruni, Eugenio Garofalo, Federico Longhini, Claudia Crimi, Angelantonio Maglio, Alessandro Vatrella, Girolamo Pelaia, Corrado Pelaia
Beclomethasone dipropionate/formoterol fumarate/glycopyrronium (BDP/FF/G) single inhaler extrafine triple therapy is effective for the treatment of uncontrolled asthma. Nevertheless, there is a lack of data about the use of diaphragmatic ultrasonography to monitor adult asthmatics while they are receiving inhaled treatment. We took into consideration a 78-year-old woman complaining of asthma, treated with inhaled corticosteroid/long-acting β2 -adrenergic agonist (ICS/LABA), characterized by an asthma control questionnaire-5 (ACQ-5) score and a lung function test suggestive of uncontrolled asthma...
2024: Frontiers in Medicine
#8
JOURNAL ARTICLE
Paola Maria Cutroneo, Elena Arzenton, Fabiana Furci, Fabio Scapini, Maria Bulzomì, Nicoletta Luxi, Marco Caminati, Gianenrico Senna, Ugo Moretti, Gianluca Trifirò
BACKGROUND: The management of uncontrolled severe asthma has greatly improved since the advent of novel biologic therapies. Up to August 2022, five biologics have been approved for the type 2 asthma phenotype: anti-IgE (omalizumab), anti-IL5 (mepolizumab, reslizumab, benralizumab), and anti-IL4 (dupilumab) monoclonal antibodies. These drugs are usually well tolerated, although long-term safety information is limited, and some adverse events have not yet been fully characterized. Spontaneous reporting systems represent the cornerstone for the detection of potential signals and evaluation of the real-world safety of all marketed drugs...
May 2024: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
#9
JOURNAL ARTICLE
Anna-Rebekka Staufenberg, Hanna K Frankenberger, Ulrike Förster-Ruhrmann, Franziska C Spahn, Ludger Klimek, Kai Fruth, Clemens Stihl, Christoph Matthias, Moritz Gröger, Jan Hagemann
BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type‑2 inflammatory disease of the upper airways, with severe impairment of quality of life. Persons affected by NSAID-exacerbated respiratory disease (NERD) usually present with highly dynamic recurrence of polyps and disease despite prior treatment with sinus surgeries, oral corticosteroids, and aspirin desensitization (ATAD). Biologic therapy has fundamentally changed the choice of therapeutic concept; however, limited data exist on subgroups such as NERD patients...
March 11, 2024: HNO
#10
JOURNAL ARTICLE
Natalie E Rudsenske, Jessica B Perkins
Background: Research surrounding the coronavirus disease 2019 (COVID-19) pandemic and its impact on patients who are atopic has mainly focused on adults. After the delta variant showed increased rates of COVID-19 in children, the pediatric population needs to be assessed as well. Objective: The objective was to assess and report outcomes in patients with COVID-19 and with and without certain atopic diseases in our patient cohort at the University of Mississippi Medical Center. Methods: We conducted a retrospective review of patients by using a de-identified data base that allows querying via medical claims codes from the University of Mississippi Medical Center's Research Data Warehouse...
March 1, 2024: Allergy and Asthma Proceedings:
#11
JOURNAL ARTICLE
Marek Lommatzsch
PURPOSE OF REVIEW: To review the current concepts of remission in asthma. RECENT FINDINGS: Until 2023, asthma guidelines have been promoting the concept of disease control, recommending the step-wise addition of drugs until the best possible disease control is achieved. With the advent of highly effective, anti-inflammatory disease-modifying antiasthmatic drugs (DMAADs), treatment goals of asthma have changed. Several national guidelines have now announced remission as a general treatment goal in asthma...
February 29, 2024: Current Opinion in Pulmonary Medicine
#12
JOURNAL ARTICLE
Maria Basagaña, Carlos Martínez-Rivera, Clara Padró, Ignasi Garcia-Olivé, Mimar Martínez-Colls, Juan Navarro, Laura Pardo, Paula Cruz, Gloria Cardona Peitx, Lídia Carabias, Albert Roger, Jorge Abad, Antoni Rosell
BACKGROUND: Some patients with severe asthma may benefit from treatment with biologics, but evidence has been mostly collected from randomized controlled trials (RCTs), in which patients' characteristics are different from those encountered in asthma patients in the real-world setting. The aim of this study was to describe the clinical features of complete responders versus non-complete responders to long-term treatment with biologics in patients with severe asthma attended in routine daily practice...
December 2024: Annals of Medicine
#13
REVIEW
James G Krings, Richard Beasley
The Global Initiative of Asthma (GINA) recommends that short-acting beta2 -agonist (SABA) monotherapy should no longer be prescribed, and that as-needed combination inhaled corticosteroid (ICS)-formoterol is the preferred reliever therapy in adults and adolescents with mild asthma. These recommendations are based on the risks of SABA monotherapy, the evidence that ICS-formoterol reliever therapy markedly decreases the occurrence of severe asthma exacerbations when compared to SABA reliever therapy alone, and because ICS-formoterol reliever therapy has a favourable risk/benefit profile when compared with maintenance ICS plus SABA reliever therapy...
January 16, 2024: Journal of Allergy and Clinical Immunology in Practice
#14
Ryu Sekiya, Tomoyuki Soma, Kazuyuki Nakagome, Makoto Nagata
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic necrotizing vasculitis accompanied by granulomas and eosinophilic inflammation, exhibiting marked peripheral blood eosinophiliaandasthma. Neuropathy is a difficult-to-treat common manifestation that frequently remains after achieving clinical remission with current therapy in a subpopulation of patients with EGPA with or without life-threatening organ involvement. Refractory neuropathy regularly reduces the quality of life and requires glucocorticoids (GCs) and/or immunosuppressants for a long time...
January 2024: Curēus
#15
JOURNAL ARTICLE
Alexandra M Nanzer, Anne-Catherine Maynard-Paquette, Vardah Alam, Linda Green, Louise Thomson, Jodie Lam, Mariana Fernandes, Cris Roxas, Grainne d'Ancona, Andrew Hearn, Jessica Gates, Sangita Agarwal, Brian D Kent, Michelle Fernando, David P D'Cruz, Claire Hopkins, Tevfik F Ismail, Jaideep Dhariwal, David J Jackson
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a multi-systemic disease characterised by eosinophilic tissue inflammation. Benralizumab, an anti-IL-5-receptor monoclonal antibody, induces rapid depletion of eosinophils; its longer-term effect in EGPA is unknown. OBJECTIVE: To assess the real-world effectiveness and clinical remission rates of anti-IL5R therapy in EGPA METHODS: We performed a retrospective cohort analysis of EGPA patients, who commenced treatment with benralizumab...
January 9, 2024: Journal of Allergy and Clinical Immunology in Practice
#16
JOURNAL ARTICLE
Carla Maria Irene Quarato, Pasquale Tondo, Donato Lacedonia, Piera Soccio, Paolo Fuso, Eugenio Sabato, Anela Hoxhallari, Maria Pia Foschino Barbaro, Giulia Scioscia
Background. Nowadays, highly selective biological drugs offer the possibility of treating severe type 2 asthma. However, in the real-life setting, it is crucial to confirm the validity of the chosen biological treatment by evaluating the achievement of clinical remission. Study purpose. The main aims of this real-life study were to evaluate the efficacy of dupilumab in terms of clinical, functional, and inflammatory outcomes at 6, 12, 18, and 24 months of treatment and to estimate the percentage of patients achieving partial or complete clinical remission at 12 and 24 months of treatment...
January 4, 2024: Journal of Clinical Medicine
#17
JOURNAL ARTICLE
Tomonori Ishii, Hideaki Kunishige, Tamami Kobayashi, Etsuko Hayashi, Masaki Komatsubara, Takeo Ishii, Rafael Alfonso-Cristancho, Jun Tamaoki, Peter Howarth
OBJECTIVES: : Assess real-world, long-term safety/effectiveness of mepolizumab for eosinophilic granulomatosis with polyangiitis (EGPA) in Japan. METHODS: : MARS (GSK ID:213684/NCT04551989) is an ongoing 96-week study of patients with EGPA who received 4-weekly mepolizumab 300 mg subcutaneously for ≥96 weeks before study entry (baseline) and continued treatment. This interim analysis included safety from baseline to Week 48 (observation period) and clinical outcomes before mepolizumab and during the observation period...
December 8, 2023: Modern Rheumatology
#18
JOURNAL ARTICLE
Neşe Merve Güner Zirih, Bilge Yilmaz Kara, Songül Özyurt, Oğuzhan Okçu, Tuğba İlgar, Ünal ŞahiN
INTRODUCTION: High-dose and long-term use of inhaled corticosteroids may cause systemic and local side effects such as opportunistic infections. Here we report a patient with asthma who developed a giant cavity in the lung while using inhaled salmeterol plus fluticasone propionate. CASE STUDY: A 57-year-old female patient presented with a three-week history of cough, hemoptysis, and dyspnea. She had a diagnosis of asthma for 4 years and was using an inhaled salmeterol plus fluticasone treatment intermitently for 2 years...
December 11, 2023: Journal of Asthma
#19
JOURNAL ARTICLE
Nouf Ahmed Alhammadi, Saud Mushabbab Mohammed Al Oudhah, Mofareh Ahmed Mofareh Asiri, Mohammed Abdullah Alshehri, Bassam Ahmed B Almutairi, Abdullah Mohammed Abdullah Thalibah, Fahad Nasser Mohammed Asiri, Abdullah Saad Aldarani Alshahrani
BACKGROUND: Corticosteroids have been used since the 50s and it represent the most important and frequently used class of anti-inflammatory and immunosuppressive drugs for the treatment of several diseases such as numerous neoplastic, asthma, allergy, rheumatoid arthritis, and dermatological disorders. This study aims to determine the public awareness of side effects of systemic steroids in Asir region, Saudi Arabia. METHODS: A descriptive cross-sectional web-based study was used...
September 2023: Journal of Family Medicine and Primary Care
#20
Kayoko Kawashima, Osamu Matsuno, Mika Okuno, Takanari Kawabe, Yukiko Hanada
Eosinophilic chronic rhinosinusitis (ECRS) is a type 2 inflammatory disease that frequently co-occurs with bronchial asthma. The current treatment options for ECRS include endoscopic sinus surgery and oral corticosteroid therapy (OCS). However, recurrence after surgery is common, and OCS therapy may cause side effects. We present the case of a 74-year-old woman with severe asthma, ECRS, and secretory otitis media with possible eosinophilic otitis media, who experienced significant improvement in both conditions after treatment with tezepelumab, an anti-thymic stromal lymphopoietin (TSLP) antibody...
October 2023: Curēus
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
